Serina Therapeutics, Inc. (SER)
NYSEAMERICAN: SER · Real-Time Price · USD
6.82
+0.06 (0.89%)
Oct 31, 2024, 4:00 PM EDT - Market closed
Company Description
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain.
Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy.
In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases.
Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
Serina Therapeutics, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Nov 29, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Steven Ledger |
Contact Details
Address: 601 Genome Way, Suite 2001 Huntsville, Alabama 35806 United States | |
| Phone | 256 327 9630 |
| Website | serinatherapeutics.com |
Stock Details
| Ticker Symbol | SER |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001708599 |
| ISIN Number | US81751A1088 |
| Employer ID | 82-1436829 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Steven A. Ledger | Interim Chief Executive Officer and Director |
| Dr. Randall W. Moreadith M.D., Ph.D. | Chief Scientific Officer |
| Dr. Balkrishan Gill Ph.D. | Executive Chairman |
| Dr. Srini Tenjarla | Senior Vice President of Chemistry, Manufacturing and Controls and Formulation |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 2, 2024 | 8-K | Current Report |
| Sep 12, 2024 | 8-K | Current Report |
| Sep 5, 2024 | 8-K | Current Report |
| Aug 23, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 16, 2024 | 8-K | Current Report |
| Aug 9, 2024 | 8-K | Current Report |
| Aug 9, 2024 | 10-Q | Quarterly Report |
| Jul 29, 2024 | 8-K | Current Report |
| Jul 18, 2024 | 8-K | Current Report |
| Jul 12, 2024 | 8-K | Current Report |